Adjustment of endogenous concentrations in pharmacokinetic modeling
- 280 Downloads
Estimating pharmacokinetic parameters in the presence of an endogenous concentration is not straightforward as cross-reactivity in the analytical methodology prevents differentiation between endogenous and dose-related exogenous concentrations. This article proposes a novel intuitive modeling approach which adequately adjusts for the endogenous concentration.
Monte Carlo simulations were carried out based on a two-compartment population pharmacokinetic (PK) model fitted to real data following intravenous administration. A constant and a proportional error model were assumed. The performance of the novel model and the method of straightforward subtraction of the observed baseline concentration from post-dose concentrations were compared in terms of terminal half-life, area under the curve from 0 to infinity, and mean residence time.
Mean bias in PK parameters was up to 4.5 times better with the novel model assuming a constant error model and up to 6.5 times better assuming a proportional error model.
The simulation study indicates that this novel modeling approach results in less biased and more accurate PK estimates than straightforward subtraction of the observed baseline concentration and overcomes the limitations of previously published approaches.
KeywordsEndogenous concentration Intrinsic concentration Baseline adjustment Pre-dose concentration Pharmacokinetics
We gratefully acknowledge the editorial expertise of Karima Benamara and the helpful comments from Werner Engl.
The authors made equal contributions to the development of this manuscript.
- 1.Howard DR (2004) Development considerations for biological data. In: Bonate PL, Howard DR (eds) Pharmacokinetics in drug development: regulatory and development paradigms. Volume 2. American Association of Pharmaceutical Scientists, Arlington, pp 359–380Google Scholar
- 5.Gabrielsson J, Weiner D (2000) Pharamcokinetic and pharmacodynamic data analysis: concepts and applications, 4th edn. Swedish Pharmaceutical, StockholmGoogle Scholar